Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memory NK Cell Therapy for Advanced Metastatic Solid Tumors
NCT07274449Phase 2Active, not recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in malignant solid tumor, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Dose-limiting toxicities at 1 year. Started May 2025; status: active, not recruiting.
02
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07274449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274449.